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Summary
Purpose: We reviewed our experience with ACTH for the treatment of intractable
generalized seizures other than spasms.
Methods: Efficacy and adverse effects of ACTH against intractable generalized
seizures other than spasms were retrospectively investigated in 15 patients treated
between 1991 and 2003. The median age of the patients at ACTH therapy was 42
months. The targeted type of seizure was brief tonic in 6, atypical absence in 6, atonic
in 2, and myoclonic in 1. The dose of ACTH was 0.01—0.015 mg/kg in most patients.
The effect of ACTH was determined at the end of ACTH therapy, and 3 months and 1
year after ACTH therapy.
Results: Seizure freedom was obtained in 13 of 15 patients. However, 6 of them had a
recurrence of seizures within 3 months after ACTH therapy. ACTH was the most
effective in patients with atypical absence seizures. Statistical analysis showed that
the number of injection and total dose of ACTH were smaller in patients with atypical
absence seizures than in those with brief tonic seizures. Adverse effects were
frequent but serious one was not observed.
Conclusion: ACTH therapy was effective in patients with intractable generalized
seizures other than spasms. However, its efficacy was often transient. ACTH can be
useful for generalized seizures other than spasms but its limitation should be
considered.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +81 3 3813 3111; fax: +81 3 5800 1580.
E-mail address: okumura@med.juntendo.ac.jp (A. Okumura).
1059-1311/$ — see front matter # 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.seizure.2006.05.010
470 A. Okumura et al.Introduction
It is generally accepted that adrenocorticotropic hor-
mone (ACTH) is useful for the treatment of West
syndrome. Practice parameter of the AmericanAcad-
emy of Neurology and the Child Neurology Society
reportedthatACTHisprobablyeffectivefortheshort-
term treatment of infantile spasms on the basis of
detailed reviewofMEDLINE.1 In addition, Oguni et al.
described that ACTH is effectiveeven inpatientswith
epileptic spasms without hypsarrhythmia.2 ACTH or
steroids have also beenused forpatientswith intract-
able epilepsy other than West syndrome. However,
the role of ACTH in the treatment of epilepsy other
thanWestsyndromeremainsuncertain.Wereportour
experience with ACTH for the treatment of general-
ized seizures other than spasms.Patients and method
We retrospectively investigated the efficacy and
adverse effects of ACTH therapy against generalized
seizures other than epileptic spasms. There were 15
patients (7 boys and 8 girls) in whom ACTH therapy
was performed against generalized seizures other
than epileptic spasms in Department of Pediatrics,
Nagoya University Hospital between 1991 and 2003.
Their seizures were refractory to oral antiepileptic
drugs including valproate, clonazepam or clobazam,Table 1 Clinical characteristics of the patients
Patient Sex Age at the
onset (m)
MR Etiology
1 F 19 Severe 22q11.2 deletion
syndrome
Sequelae of statu
epilepticus
2 F 9 Moderate Unknown
3 F 39 Mild Unknown
4 F 18 Severe Unknown
5 M 33 Severe Sequelae of acute
encephalopathy
6 M 4 Severe Unknown
7 M 20 Severe Unknown
8 M 98 None Unknown
9 F 22 Severe Unknown
10 F 3 Severe Unknown
11 F 84 Mild Unknown
12 F 9 Severe Angelman syndro
13 M 23 Mild Hemimegalencep
14 M 10 Moderate Unknown
15 M 3 Severe Unknown
MR: mental retardation, CP: cerebral palsy, WS:West syndrome, SE-M
symptomatic generalized epilepsy, FLE: frontal lobe epilepsy, CSWSand phenytoin. At least two of these drugs had been
administered at maximal tolerable dose in all
patients before ACTH therapy. Clinical characteris-
tics of the patients are shown in Table 1. The median
age at the onset of epilepsy was 19 months (range,
3—98 months). Etiology of epilepsy was identified in
four patients: 22q11.2 deletion syndrome in one,
sequelae of acute encephalopathy in one, Angelman
syndrome in one, and hemimegalencephaly in one.
Etiology was unknown in the other 11 patients. MRI
revealed diffuse atrophy in three patients and left
hemimegalencephaly in 1. In the other 11 patients,
MRI findings were unremarkable.
The type of the seizures was determined on the
basis of ictal simultaneous video-EEG recordings in
all patients. Interictal EEG did not show hypsar-
rhythmia in any patients during the study period,
although four patients had a prior history of West
syndrome. Epilepsy syndrome was clinically deter-
mined on the basis of types of seizures, EEG findings,
neuroimaging, and other clinical findings.
The median age of the patients at ACTH therapy
was 42 months (range, 18—111 months). In three
patients who had two types of seizures, the target
type of seizure was determined before ACTH ther-
apy was started. The target type of seizure was brief
tonic in 6, atypical absence in 6, atonic in 2, and
myoclonic in 1. The dose of ACTH was usually 0.01—
0.015 mg/kg that was similar to that used for
patients with West syndrome in our hospital. ACTHEpilepsy
syndrome
Prior history
of WS
MRI findings
SE-MISF No Diffuse atrophy
s
S-GE Yes Unremarkable
S-GE No Unremarkable
S-GE No Unremarkable
S-GE No Diffuse atrophy
S-GE Yes Unremarkable
S-GE No Unremarkable
FLE No Unremarkable
S-GE No Unremarkable
S-GE No Unremarkable
CSWS No Unremarkable
me S-GE No Unremarkable
haly S-GE No Left
hemimegalencephaly
S-GE Yes Unremarkable
S-GE Yes Diffuse atrophy
ISF: severe epilepsy with multiple independent spike foci, S-GE:
: epilepsy with continuous spike-waves during slow wave sleep.
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Table 2 ACTH therapy and its effect
Patient Age at
ACTH
therapy (m)
Target
type of
seizure
Frequency of
target type of
seizure (day1)
Other
seizure
types
Dose of
ACTH
(mg/kg)
Number
of
injection
Total dose
of ACTH
(mg/dl)
Short-term
effect
Middle-term
effect
Long-term
effect
1 35 Brief tonic 15 None 0.014 26 0.364 Effective Poor Poor
2 18 Brief tonic 10 None 0.01 14 0.14 Effective Poor Poor
3 42 Brief tonic 50 None 0.017 25 0.425 Effective Excellent Excellent
4 34 Brief tonic >100 None 0.014 23 0.322 Effective Poor Poor
5 47 Brief tonic 20 None 0.013 25 0.325 Partially
effective
Poor Poor
6 71 Brief tonic 50 None 0.025 22 0.55 Effective Poor Poor
7 38 AA 5 Atonic 0.011 14 0.154 Effective Excellent Excellent
8 111 AA 10 CPS 0.008 14 0.112 Effective Poor Poor
9 58 AA 5 Myoclonic 0.01 20 0.2 Effective Excellent Poor
10 73 AA 5 Brief tonic 0.013 24 0.312 Effective Excellent Excellent
11 92 AA 10 None 0.008 14 0.112 Effective Excellent Excellent
12 48 AA 20 None 0.015 15 0.225 Effective Excellent Excellent
13 26 Atonic 10 None 0.01 14 0.14 Effective Excellent Excellent
14 23 Atonic >100 None 0.015 17 0.255 Partially
effective
Poor Poor
15 31 Myoclonic 10 None 0.01 21 0.21 Effective Poor Poor
AA: atypical absence, CPS: complex partial seizure.
472 A. Okumura et al.was daily injected intramuscularly for the first 2
weeks in all patients. Thereafter, the duration and
dosage was according to seizure frequency, EEG
findings, and severity of adverse effects.
The effect of ACTH was determined at the follow-
ing three points: short-time effect at the end of
ACTH therapy, middle-term effect at 3 months after
ACTH therapy, and long-term effect at 1 year after
ACTH therapy. The short-term effect of ACTH ther-
apy was classified into three categories: effective,
when the target type of seizures disappeared; par-
tially effective, when 50% or more reduction of the
target type of seizures was obtained but they per-
sisted; ineffective, when only less than 50% reduc-
tion was obtained. Themiddle- and long-term effect
was classified in the following three categories:
excellent, complete disappearance of the target
type of seizures; good, the target type of seizures
was present but their frequency was 50% or less
before ACTH therapy; poor, less than 50% reduction
of the target types of seizures. Electroencephalo-
grams (EEGs) were recorded at least before and at
the end of ACTH therapy.
The psychomotor development of the patients at
the time of ACTH therapy was normal in 1 patient,Table 3 EEG findings and antiepileptic drugs before and a
Patient Interictal EEG before
ACTH therapy
Interictal EEG at th
end of ACTH therap
1 Multiple independent
focal spikes
Multiple independe
focal spikes
2 Diffuse polyspike-waves Normal
3 Diffuse polyspike-waves Diffuse polyspike-w
4 Diffuse polyspike-waves Diffuse polyspike-w
5 Diffuse polyspike-waves Diffuse polyspike-w
6 Diffuse polyspike-waves Diffuse polyspike-w
7 Diffuse polyspike-waves Diffuse polyspike-w
8 Diffuse spike-waves Normal
9 Diffuse slow spike-waves Diffuse slow spike-w
10 Diffuse slow spike-waves Diffuse slow spike-w
11 Continuous spike-waves
during sleep
Right frontal domin
spike-waves
12 Diffuse slow spike-waves Diffuse slow spike-w
13 Diffuse slow spike-waves Left dominant slow
14 Diffuse slow spike-waves Diffuse slow spike-w
15 Diffuse slow spike-waves Diffuse slow spike-w
VPA: valproate, PHT: phenytoin, CZP: clonazepam, DZP: diazepam,mildly retarded in 3, moderately retarded in 2, and
severely retarded in 9. Spastic cerebral palsy was
not observed in any patients.
Statistical analysis between two groups was per-
formed using Student’s t-test for numerical vari-
ables and Fisher’s exact probability test for
categorical variables. A value of p < 0.05 was con-
sidered to be statistically significant.Results
The results are summarized in Table 2. Short-term
effect of ACTH was effective in 13 patients and
partially effective in 2. However, 6 of 13 patients
whose seizures disappeared had a recurrence of the
target types of seizures within 3 months after ACTH
therapy. A recurrence of the seizures within a month
after ACTH therapy was observed in 5 of them. One
additional patient had a seizure recurrence 4
months after ACTH therapy. Eventually, a cessation
of the target type of seizure after a year after ACTH
was seen in six patients.
EEG findings and antiepileptic drugs before and
after ACTH therapy was shown in Table 3. EEG wasfter ACH therapy
e
y
Antiepileptic drugs
before ACTH therapy
Antiepileptic drugs
after ACTH therapy
nt VPA 700 mg,
PHT 75 mg,
CZP 1.1 mg
PHT 90 mg,
CZP 1.1 mg
VPA 550 mg VPA 300 mg
aves VPA 600 mg VPA 600 mg
aves CZP 0.4 mg CZP 0.8 mg
aves VPA 500 mg,
CZP 0.3 mg
VPA 500 mg,
PHT 150 mg
aves VPA 1200 mg,
PHT 230 mg,
CLB 6 mg
VPA 1200 mg,
PHT 230 mg
aves VPA 700 mg,
CZP 0.5 mg
VPA 700 mg,
CZP 0.5 mg
VPA 800 mg,
DZP 5 mg
PHT 150 mg
aves VPA 700 mg,
CLB 13 mg
VPA 700 mg,
CLB 13 mg
aves PHT 120 mg,
CZP 0.5 mg
PHT 120 mg,
CLB 4 mg
ant VPA 700 mg,
CLB 18 mg
CLB 12 mg
aves CZP 0.9 mg CZP 0.3 mg
waves VPA 500 mg,
CZP 0.5 mg
CZP 0.7 mg
aves VPA 600 mg VPA 600 mg
aves VPA 900 mg,
PB 30 mg
VPA 900 mg
CLB: clobazam, PB: phenobarbital.
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Table 4 Comparison between those with brief tonic seizures and atypical absence seizures
Brief tonic
seizures (n = 6)
Atypical absence
seizures (n = 6)
p-Value
Age at ACTH therapy (months) 41  18 70  28 0.057
Interval between the onset and
ACTH therapy (months)
21  23 31  23 0.48
Seizure cessation 5 (83%) 6 (100%) 0.50
Dose of ACTH (mg/kg) 0.015  0.005 0.11  0.003 0.080
Number of injection 22.5  4.4 16.8  4.2 0.046
Total dose of ACTH (mg/kg) 0.35  0.14 0.19  0.08 0.024
Recurrence of seizure 4/5 (80%) 2/6 (33%) 0.18
Severe mental retardation 4 (67%) 4 (67%) >0.99normalized in two patients (patients 2 and 8). A
focalizationof paroxysmal dischargeswas recognized
in other two patients (patients 11 and 13). Paroxys-
mal discharges persisted in the remaining 11
patients. However, the frequency and amplitudes
of paroxysmal discharges were remarkably reduced
in most patients. The dose and/or number of anti-
epileptic drugs were reduced in eight patients. Drugs
werenot altered in four patients. The replacement of
drugs was made in two patients. The increase of the
dose of antiepileptic drugs was seen in one patient.
As to brief tonic seizures, seizure cessation was
obtained five of six patients. However, four patients
had a recurrence within 3 months after ACTH ther-
apy. Seizure cessation was observed in all six
patients whose target type of seizures was atypical
absence. All but one patient remained free from
seizures 1 year after ACTH therapy. Atonic seizures
were controlled by ACTH therapy in one of two
patients. Seizure freedom persisted 1 year after
ACTH therapy in the patient whose seizures disap-
peared after ACTH therapy. As to one patient with
myoclonic seizures, seizure cessation was obtained
after ACTH therapy, but seizures recurred within a
week after ACTH therapy.
Statistical analyses were performed between
brief tonic and atypical absence seizures
(Table 4). Age at ACTH therapy was relatively older
in those with atypical absences. The number ofTable 5 Adverse effects of ACTH therapy
Adverse effects Number of patients
Irritability 15 (100%)
Central obesity 15 (100%)
Hypokalemia <3 mEq/l 7 (47%)
Edema 2 (13%)
Elevated hepatic function 1 (7%)
Hyperthermia without infection 1 (7%)
Hypertension 1 (7%)
Infection 1 (7%)
Thrush 1 (7%)injection and total dose of ACTH were significantly
smaller in patients with atypical absence seizures
than in those with brief tonic seizures. Seizure
recurrence was relatively rare in those with atypical
absence seizures, but there was no significant dif-
ference. The interval between the onset of epilepsy
and ACTH therapy was not correlated with seizure
cessation or recurrence of seizures.
Adverse effects of ACTH therapy are summarized
in Table 5. Irritability and central obesity was
observed in all patients. Hypokalemia (serum potas-
sium level below 3 mEq/l) was also frequent.
Although several other adverse effects were
observed in some patients, serious one was not
observed in any patients.Discussion
Our study demonstrated that seizure cessation was
obtained by ACTH therapy in 13 of 15 patients with
generalized seizures other than spasms. However, 6
of 13 responders had a recurrence within 3 months
after ACTH therapy. These results were consistent
with several previous studies on ACTH or steroid
therapy for intractable epilepsy other than West
syndrome. Snead et al. stated that 12 of 18 patients
with intractable seizures other than infantile
spasms became seizure free after treatment with
ACTH or steroid, but recurrent seizures were
observed in 6 of 12 responders.3 Sinclair reported
that 46% of patients became seizure free and 40%
had a significant decrease in seizure frequency after
predonisolone therapy.4 Verhelst et al. described
that 25% of patients treated with steroid became
seizure free, 11% had a seizure reduction of >50%,
and 11% had a seizure reduction of <50%.5 In their
series, 11 of 17 responders experienced a seizure
recurrence.5 These facts indicates that ACTH will be
effective for cessation of seizures other than spasms
but its effect may be transient in about half of the
responders. We consider that ACTH can be an option
474 A. Okumura et al.of therapy in patients with intractable epilepsy
other than West syndrome but the limitation of
the effect should be understood. ACTH may be
indicated to tide the patient over a particularly
difficult period as Aicardi described in his textbook.6
There have been few studies on the difference in
efficacy of ACTH or steroids according to the types
of seizures. Our study suggested that ACTH will be
more effective for atypical absence seizures than
for brief tonic seizures. The number of injection and
total dose of ACTH were significantly smaller in
patients with atypical absence seizures than in
those with brief tonic seizures. Most of patients
with either type of seizures once became seizure
free. However, all but one patient with brief tonic
seizures had recurrent seizures. On the other hand,
recurrent seizures were observed in only two of six
patients with atypical absence seizures. Some
authors described that results of hydrocortisone
therapy were better in tonic and tonic-clonic sei-
zures than in absences.7 In contrast, Sinclair
reported that the best outcome of predonisolone
therapy was seen in which six of seven patients
became seizure free.4 These differences may be
attributable to several factors such as the drugs
used for treatment, the dose of the drug, duration
of the therapy, outcome measure, and the length of
follow-up. Further studies are necessary in order to
clarify the type of seizures against which ACTH is
effective.
Japanese pediatric neurologists have tried short
and low dose ACTH therapy to West syndrome.8—10
Ito et al. revealed that the initial effects of ACTH on
seizures and long-term outcome were not dose
dependent when the daily dose of ACTH was
between 0.005 and 0.032 mg/kg. However, the opti-
mal dose of ACTH and duration of the therapy has
not been elucidated in patients with seizures other
than spasms. In our study, daily dose of ACTH was
0.015 mg/kg or less in 13 of 15 patients. The max-
imum number of injection was 26. These results
suggest that relatively low dose of ACTH will not
be inferior to classical dose of ACTH reported in the
previous literatures.3—5 However, the optical regi-
men for seizures other than spasms should be deter-
mined by further trials.
It is interesting that ACTH was effective in most
patients despite that the remarkable improvementof
EEG findings was observed only in a few patients.
Sinclair described that the improvement of seizures
in patients treated with predonisone was usually
associated with normalization of the EEG.4 In the
series of Verhelst et al., the improvement of EEG
was noticed in all responders to steroids.5 This dif-
ference may be attributable to the difference of
evaluation of EEGfindings. In our patients, the reduc-tion of frequency and amplitudes of paroxysmal dis-
charges was observed in most patients in whom
paroxysmal discharges persisted after ACTH therapy.
Adverse effects of ACTH were frequent but were
not serious in our patients. The most frequent was
irritability and central obesity. Hypokalemia was
also frequent, whereas infection was seen in only
one patient. We consider that ACTH therapy will be
safe in patients with generalized seizures other than
spasms. The safety of ACTH therapy will be partly
attributable to low dose of ACTH and relatively short
duration of the therapy.
The important feature of our study is that we
determined the targeted type of seizures before the
treatment. This will be particularly important in
patients with two or more types of seizures. Two
or more types of seizures can be present at some
period in a single patient, especially one with epi-
leptic encephalopathy such as Lennox-Gastaut syn-
drome. In patients with a prior history of West
syndrome, the type of seizures may gradually
change from spasms into other types of seizures
such as brief tonic or myoclonic seizures. The deter-
mination of type of seizures is very difficult without
ictal VTR-EEG recordings in such patients. We make
it a rule to record ictal VTR-EEG in all patients who
can be candidates of ACTH therapy in order to
evaluate its efficacy for seizures and EEG. Accord-
ingly, we could examine a difference of efficacy in
different types of seizures. Further studies on ACTH
therapy for seizures other than spasms should be
performed after the targeted type of seizures is
strictly determined.
In conclusion, ACTH therapy was effective in the
majority of patients with refractory generalized
seizures other than spasms. However, its efficacy
is often transient, especially in patients with brief
tonic seizures. On the other hand, seizure freedom
without recurrence can be achieved in the majority
of patients with atypical absence seizures. We
consider that ACTH can be useful for generalized
seizures other than spasms but its limitation should
be considered.References
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